{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:50:29Z","timestamp":1790869829261,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal antibody therapy with rituximab in combination with standard chemotherapy has improved the survival of patients with advanced-stage follicular lymphoma (FL). A series of next-generation anti-CD20 antibodies may be less immunogenic and have even greater antitumor activity through augmented interactions with host effector mechanisms responsible for tumor cell kill. Additional approaches with patient-specific immunoglobulin idiotype vaccines; novel monoclonal antibodies binding to biologically active cell-surface antigen are also demonstrating early clinical activity. Antibodies targeting radioisotopes, toxins or drugs are also slowly entering clinical trials and practice. Last, allogeneic stem cell transplantation following reduced-intensity conditioning provides graft-versus-tumor immune responses that may be able to control FL and allow this risky but potentially curative treatment option to older patents or those with comorbidities.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.226","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"226-232","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects"],"prefix":"10.1182","volume":"2007","author":[{"given":"David G.","family":"Maloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703251679800_R1","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143\u20134149.","DOI":"10.1200\/JCO.2006.05.8198"},{"key":"2019111703251679800_R2","doi-asserted-by":"crossref","unstructured":"Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754\u2013758.","DOI":"10.1182\/blood.V99.3.754"},{"key":"2019111703251679800_R3","doi-asserted-by":"crossref","unstructured":"Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940\u20133947.","DOI":"10.1200\/JCO.2003.05.013"},{"key":"2019111703251679800_R4","doi-asserted-by":"crossref","unstructured":"Hagenbeek A, Plesner T, Johnson P, et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: results of a phase I\/II trial in relapsed or refractory follicular non-Hodgkins\u2019s lymphoma [abstract]. Blood. 2005;106:4760a.","DOI":"10.1182\/blood.V106.11.4760.4760"},{"key":"2019111703251679800_R5","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Leonard JP, Coiffier B, et al. Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin\u2019s lymphoma [abstract]. Blood. 2005;106:2428a.","DOI":"10.1182\/blood.V106.11.2428.2428"},{"key":"2019111703251679800_R6","doi-asserted-by":"crossref","unstructured":"Morshhauser F, Leonard JP, Coiffier B, et al. Phase I\/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL [abstract]. J Clin Oncol. 2006;24: abstract no. 7530.","DOI":"10.1200\/jco.2006.24.18_suppl.7530"},{"key":"2019111703251679800_R7","doi-asserted-by":"crossref","unstructured":"Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005;28:212\u2013219.","DOI":"10.1097\/01.cji.0000155050.03916.04"},{"key":"2019111703251679800_R8","doi-asserted-by":"crossref","unstructured":"Weiner GJ, Bowles JA, Link BK, Campbell MA, Wooldridge JE, Breitmeyer JB. anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R) [abstract]. Blood. 2005;106:348a.","DOI":"10.1182\/blood-2006-04-020057"},{"key":"2019111703251679800_R9","doi-asserted-by":"crossref","unstructured":"Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738\u20132743.","DOI":"10.1182\/blood-2003-06-2031"},{"key":"2019111703251679800_R10","doi-asserted-by":"crossref","unstructured":"Umana P, Moessner E, Bruenker P, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction [abstract]. Blood. 2006;108:229a.","DOI":"10.1182\/blood.V108.11.229.229"},{"key":"2019111703251679800_R11","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Thall A, Witzig TE, et al. Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005;23:4390\u20134398.","DOI":"10.1200\/JCO.2005.09.018"},{"key":"2019111703251679800_R12","doi-asserted-by":"crossref","unstructured":"Leonard J, Friedberg J, Younes A, et al. A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007;18:1216\u20131223.","DOI":"10.1093\/annonc\/mdm114"},{"key":"2019111703251679800_R13","doi-asserted-by":"crossref","unstructured":"Advani R, Forero-Torres A, Furman RR, et al. SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non- Hodgkin\u2019s lymphoma: evidence of antitumor activity from a phase I study [abstract]. Blood. 2006;108:695a.","DOI":"10.1182\/blood.V108.11.695.695"},{"key":"2019111703251679800_R14","doi-asserted-by":"crossref","unstructured":"Long L, Patawaran M, Tong X, et al. Efficacy of an antagonistic anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease [abstract]. Blood. 2006;108:230a.","DOI":"10.1182\/blood.V108.11.230.230"},{"key":"2019111703251679800_R15","doi-asserted-by":"crossref","unstructured":"Byrd JC, Flinn IW, Khan KD, et al. Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia [abstract]. Blood. 2006;108:2837a.","DOI":"10.1182\/blood.V108.11.2837.2837"},{"key":"2019111703251679800_R16","doi-asserted-by":"crossref","unstructured":"Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene. 2007;26:3704\u20133713.","DOI":"10.1038\/sj.onc.1210370"},{"key":"2019111703251679800_R17","doi-asserted-by":"crossref","unstructured":"Leonard JP, Coleman M, Ketas JC, et al. Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21:3051\u20133059.","DOI":"10.1200\/JCO.2003.01.082"},{"key":"2019111703251679800_R18","doi-asserted-by":"crossref","unstructured":"Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: phase I\/II clinical trial results. Clin Cancer Res. 2004;10:5327\u20135334.","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"2019111703251679800_R19","doi-asserted-by":"crossref","unstructured":"Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:5044\u20135051.","DOI":"10.1200\/JCO.2005.13.821"},{"key":"2019111703251679800_R20","doi-asserted-by":"crossref","unstructured":"Fayad L, Patel H, Verhoef G, et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study [abstract]. Blood. 2006;108:2711a.","DOI":"10.1182\/blood.V108.11.2711.2711"},{"key":"2019111703251679800_R21","doi-asserted-by":"crossref","unstructured":"Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocytemonocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171\u20131177.","DOI":"10.1038\/13928"},{"key":"2019111703251679800_R22","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial. Blood. 1997;89:3129\u20133135.","DOI":"10.1182\/blood.V89.9.3129"},{"key":"2019111703251679800_R23","doi-asserted-by":"crossref","unstructured":"Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22:4717\u20134724.","DOI":"10.1200\/JCO.2004.06.003"},{"key":"2019111703251679800_R24","doi-asserted-by":"crossref","unstructured":"Koc ON, Redfern C, Wiernik PH, et al. Active immunotherapy with FavId(R) (Id\/KLH) following rituximab induction: long-term follow-up of response rate improvement (RRI) and disease progression in follicular lymphoma patients (pts) [abstract]. Blood. 2006;108:691a.","DOI":"10.1182\/blood.V108.11.691.691"},{"key":"2019111703251679800_R25","doi-asserted-by":"crossref","unstructured":"Timmerman JM, Vose J, Levy R, Mayo M, Denney D. Long-term follow-up of patients treated in a phase 2 trial with MyVax(R) personalized immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin\u2019s lymphoma (NHL) [abstract]. Blood. 2005;106:2438a.","DOI":"10.1182\/blood.V106.11.2438.2438"},{"key":"2019111703251679800_R26","doi-asserted-by":"crossref","unstructured":"Freedman AS, Hamlin PA, Neelapu S, et al. Phase III trial of active immunotherapy (FavId(R), Id\/KLH) following rituximab induction therapy: clinical responses in patients (pts) with follicular non-Hodgkin\u2019s lymphoma (fNHL) [abstract]. Blood. 2006;108:2756a.","DOI":"10.1182\/blood.V108.11.2756.2756"},{"key":"2019111703251679800_R27","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Korbling M, et al. Transplantlite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817\u20132824.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2019111703251679800_R28","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390\u20133400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2019111703251679800_R29","doi-asserted-by":"crossref","unstructured":"Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma. Ann Oncol. 2003;14:737\u2013744.","DOI":"10.1093\/annonc\/mdg200"},{"key":"2019111703251679800_R30","doi-asserted-by":"crossref","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667\u2013678.","DOI":"10.1038\/sj.bmt.1703891"},{"key":"2019111703251679800_R31","doi-asserted-by":"crossref","unstructured":"Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol. 2004;127:311\u2013321.","DOI":"10.1111\/j.1365-2141.2004.05194.x"},{"key":"2019111703251679800_R32","doi-asserted-by":"crossref","unstructured":"van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521\u20133529.","DOI":"10.1182\/blood-2003-04-1205"},{"key":"2019111703251679800_R33","doi-asserted-by":"crossref","unstructured":"Rezvani AR, Sandmaier BM, Storer B, et al. Outcomes of hematopoietic stem cell transplantation (HCT) after non-myeloablative conditioning in relapsed, refractory, or transformed indolent non-Hodgkin lymphoma (NHL) [abstract]. Blood. 2006;108:3124a.","DOI":"10.1182\/blood.V108.11.3124.3124"},{"key":"2019111703251679800_R34","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595\u20133599.","DOI":"10.1182\/blood.V98.13.3595"},{"key":"2019111703251679800_R35","doi-asserted-by":"crossref","unstructured":"Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005;36:205\u2013213.","DOI":"10.1038\/sj.bmt.1705027"},{"key":"2019111703251679800_R36","doi-asserted-by":"crossref","unstructured":"Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865\u20133871.","DOI":"10.1182\/blood-2004-03-1105"},{"key":"2019111703251679800_R37","doi-asserted-by":"crossref","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310\u20134316.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2019111703251679800_R38","doi-asserted-by":"crossref","unstructured":"Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2006;12:1326\u20131334.","DOI":"10.1016\/j.bbmt.2006.08.035"},{"key":"2019111703251679800_R39","doi-asserted-by":"crossref","unstructured":"Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2004;10:2868\u20132878.","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"2019111703251679800_R40","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u20132833.","DOI":"10.1200\/JCO.1998.16.8.2825"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/226\/646262\/226_232ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/226\/646262\/226_232ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T06:58:07Z","timestamp":1588057087000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/226\/19192\/Follicular-NHL-From-Antibodies-and-Vaccines-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.226","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}